leisure time -WSS

leisure time

author：knowledge 2025-10-09 01:31:24 - browse：4

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Abortion policy in the spotlight at Republican debate

WSS

Supreme Court mifepristone arguments center on docs' right to sue

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

Roche subsidiary Foundation Medicine opens new headquarters

Vivek Ramaswamy made waves in the debate, much as in biotech

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

PBMs are inflating the cost of generic drugs. They must be reined in

Wikipedia

leisure time

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

States should stop sabotaging methadone treatment reform

Alkermes shareholders re

Scientists boost immune system in aging mice by making it youthful

Jerome Adams on the need for new antivirals for Covid

Abortion pill case raises question: who can sue the FDA?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Intellia plays down concerns on accidental germline transmission

Peter Hotez and the public health issue of online harassment

Abortion pill Supreme Court ruling could impact entire drug industry

knowledge

DeSantis wants to import drugs. Biden’s FDA blasted his plan

How to make over

Vertex Pharmaceuticals may move headquarters in Boston

How to make over

Former Pear Therapeutics executives start new VC firm

Kellogg’s is going to war over Mexico’s nutrition label rules

focus

entertainment

Wikipedia

focus